Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
  1. Home
  2. Publications
  3. Supplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial

Supplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial

Authors:
  • SGSéverine Guiu
    Séverine Guiu
  • JBJudith Balmaña
    Judith Balmaña
  • PLPablo Lemercier
    Pablo Lemercier
  • PFPhilippe Follana
    Philippe Follana
  • Anthony Gonçalves
    Anthony Gonçalves
  • FBFrédéric Bigot
    Frédéric Bigot
  • JFJean-Sébastien Frenel
    Jean-Sébastien Frenel
  • EBEtienne Brain
    Etienne Brain
  • AMAudrey Mailliez
    Audrey Mailliez
  • CBCamille Chakiba Brugere
    Camille Chakiba Brugere
  • ECElsa Curtit
    Elsa Curtit
  • ODOlfa Derbel
    Olfa Derbel

Open Access
Publisher website
Google Scholar
  • 14 November 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.30618045
Abstract
Centralized panel-NGS and Tumor PD-L1 expression analysis
Keywords
  • BREAST CANCER
  • CLINICAL TRIAL RESULTS
  • DRUG TARGETS
  • IMMUNOTHERAPY
  • CHECKPOINT BLOCKADE
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.